Candriam SCA’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $68.9M | Buy |
1,196,072
+374,452
| +46% | +$21.5M | 0.31% | 67 |
|
|
2026
Q1 | $49.8M | Sell |
821,620
-85,094
| -9% | -$4.96M | 0.26% | 88 |
|
|
2025
Q4 | $48.9M | Buy |
906,714
+9,451
| +1% | +$455K | 0.24% | 94 |
|
|
2025
Q3 | $40.5M | Sell |
897,263
-105,641
| -11% | -$4.93M | 0.21% | 108 |
|
|
2025
Q2 | $46.4M | Sell |
1,002,904
-92,461
| -8% | -$4.54M | 0.27% | 87 |
|
|
2025
Q1 | $66.8M | Sell |
1,095,365
-411,091
| -27% | -$24M | 0.42% | 50 |
|
|
2024
Q4 | $85.2M | Buy |
1,506,456
+694,811
| +86% | +$38.8M | 0.49% | 42 |
|
|
2024
Q3 | $42M | Buy |
811,645
+119,440
| +17% | +$5.6M | 0.24% | 88 |
|
|
2024
Q2 | $28.7M | Sell |
692,205
-37,921
| -5% | -$1.7M | 0.17% | 125 |
|
|
2024
Q1 | $39.6M | Buy |
730,126
+131,449
| +22% | +$6.7M | 0.25% | 92 |
|
|
2023
Q4 | $30.7M | Buy |
598,677
+186,370
| +45% | +$9.78M | 0.21% | 110 |
|
|
2023
Q3 | $23.9M | Sell |
412,307
-107,549
| -21% | -$6.59M | 0.17% | 118 |
|
|
2023
Q2 | $33.2M | Sell |
519,856
-366,724
| -41% | -$24.6M | 0.24% | 103 |
|
|
2023
Q1 | $56.6M | Buy |
886,580
+120,926
| +16% | +$8.53M | 0.39% | 62 |
|
|
2022
Q4 | $55.1M | Buy |
765,654
+324,543
| +74% | +$24.5M | 0.37% | 65 |
|
|
2022
Q3 | $31.4M | Buy |
441,111
+169,594
| +62% | +$12.3M | 0.22% | 103 |
|
|
2022
Q2 | $20.9M | Sell |
271,517
-6,757
| -2% | -$515K | 0.17% | 133 |
|
|
2022
Q1 | $20.3M | Sell |
278,274
-30,317
| -10% | -$2.04M | 0.14% | 164 |
|
|
2021
Q4 | $19.2M | Sell |
308,591
-72,359
| -19% | -$4.24M | 0.12% | 183 |
|
|
2021
Q3 | $22.5M | Sell |
380,950
-18,433
| -5% | -$1.21M | 0.15% | 155 |
|
|
2021
Q2 | $26.7M | Sell |
399,383
-1,385,399
| -78% | -$90.3M | 0.18% | 132 |
|
|
2021
Q1 | $106M | Sell |
1,784,782
-94
| -0% | -$5.85K | 0.89% | 16 |
|
|
2020
Q4 | $111M | Buy |
1,784,876
+90,350
| +5% | +$5.56M | 0.88% | 16 |
|
|
2020
Q3 | $102M | Buy |
1,694,526
+189,488
| +13% | +$11.4M | 0.96% | 17 |
|
|
2020
Q2 | $88.5M | Sell |
1,505,038
-993,760
| -40% | -$59.4M | 0.93% | 16 |
|
|
2020
Q1 | $157M | Buy |
2,498,798
+156
| +0% | +$9.54K | 1.74% | 6 |
|
|
2019
Q4 | $160M | Sell |
2,498,642
-122,364
| -5% | -$7.01M | 1.72% | 6 |
|
|
2019
Q3 | $133M | Buy |
2,621,006
+193,121
| +8% | +$9.08M | 1.76% | 8 |
|
|
2019
Q2 | $110M | Buy |
2,427,885
+454,646
| +23% | +$21.2M | 1.37% | 13 |
|
|
2019
Q1 | $94.1M | Buy |
1,973,239
+610,737
| +45% | +$30.4M | 1.2% | 14 |
|
|
2018
Q4 | $70.8M | Buy |
1,362,502
+335,865
| +33% | +$18M | 1.09% | 14 |
|
|
2018
Q3 | $63.7M | Buy |
1,026,637
+68,092
| +7% | +$4.04M | 0.85% | 20 |
|
|
2018
Q2 | $53M | Buy |
958,545
+543,285
| +131% | +$29.3M | 0.84% | 18 |
|
|
2018
Q1 | $26.3M | Sell |
415,260
-30,945
| -7% | -$1.99M | 0.45% | 47 |
|
|
2017
Q4 | $27.3M | Sell |
446,205
-176,986
| -28% | -$11.1M | 0.47% | 46 |
|
|
2017
Q3 | $39.7M | Buy |
623,191
+379,592
| +156% | +$22.2M | 0.69% | 21 |
|
|
2017
Q2 | $13.6M | Sell |
243,599
-41,549
| -15% | -$2.26M | 0.26% | 101 |
|
|
2017
Q1 | $15.5M | Sell |
285,148
-174,562
| -38% | -$9.57M | 0.3% | 84 |
|
|
2016
Q4 | $26.9M | Sell |
459,710
-83,137
| -15% | -$4.55M | 0.62% | 33 |
|
|
2016
Q3 | $29.3M | Buy |
542,847
+144,487
| +36% | +$9.28M | 0.7% | 27 |
|
|
2016
Q2 | $29.3M | Sell |
398,360
-28,691
| -7% | -$2.03M | 0.76% | 24 |
|
|
2016
Q1 | $27.1M | Buy |
427,051
+189,587
| +80% | +$12M | 0.68% | 29 |
|
|
2015
Q4 | $16.3M | Buy |
237,464
+60,934
| +35% | +$4.03M | 0.44% | 55 |
|
|
2015
Q3 | $10.5M | Sell |
176,530
-159,737
| -48% | -$10.1M | 0.26% | 116 |
|
|
2015
Q2 | $22.4M | Sell |
336,267
-381,466
| -53% | -$25.1M | 0.47% | 53 |
|
|
2015
Q1 | $46.3M | Buy |
717,733
+333,506
| +87% | +$20.9M | 0.93% | 14 |
|
|
2014
Q4 | $22.7M | Buy |
+384,227
| New | +$21.7M | 0.47% | 59 |
|
Other funds holding BMY
Candriam SCA's BMY Position: Q2 2026 in Review
Candriam SCA increased its Bristol-Myers Squibb (BMY) stake by 46% in Q2 2026, buying an estimated $21.5M and bringing the position to 1,196,072 shares worth $68.9M. The position accounts for 0.31% of the portfolio, ranked #67.
Candriam SCA first reported a position in BMY in Q4 2014 and has held it in 47 quarters since. The position peaked at $160M in Q4 2019. 2,508 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Candriam SCA held 1,196,072 shares of Bristol-Myers Squibb worth $68.9M as of Q2 2026.
- Candriam SCA bought 374,452 Bristol-Myers Squibb shares in Q2 2026, an estimated $21.5M.
- Bristol-Myers Squibb made up 0.31% of Candriam SCA's portfolio in Q2 2026, its #67 holding.
- Candriam SCA first reported a position in Bristol-Myers Squibb in Q4 2014 and has held it in 47 quarters since.
- Candriam SCA's Bristol-Myers Squibb position peaked at $160M in Q4 2019.
- 2,508 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.